Omnicell (OMCL)
(Delayed Data from NSDQ)
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
GE HealthCare Technologies (GEHC) Meets Q1 Earnings Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 0% and 3.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
by Zacks Equity Research
Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.
Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail
by Zacks Equity Research
Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes
by Zacks Equity Research
Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.
OMCL vs. PRVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OMCL vs. PRVA: Which Stock Is the Better Value Option?
Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.
Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 103.57% and 4.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Is Omnicell (OMCL) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
by Zacks Equity Research
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.
Encompass Health's (EHC) Q1 Earnings Beat, '23 EPS View Up
by Zacks Equity Research
Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.
Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 457.14% and 4.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
by Zacks Equity Research
Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.
NextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.
Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 36.80% and 72.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?